Vasgene Therapeutics, Inc
Vasgene Therapeutics, Inc
Explore linked clinical trials.2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, biliary tract disorder, bronchial neoplasm, bronchogenic carcinoma, carcinoma, endocrine system disorder, epithelial neoplasm, gallbladder disorder, gallbladder neoplasm, head and neck squamous cell carcinoma, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, pancreas disorder, pancreatic adenocarcinoma, pancreatic neoplasm, respiratory system disorder, respiratory tract neoplasm, squamous cell carcinoma | Active, not recruiting | Phase 1 | 2026-04-29 | NCT02495896 | |
| Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma | Recruiting | Phase 2 / Phase 3 | 2025-04-03 | NCT06493552 |